15-5-9　ⓔ文献

  1. Suva LJ, Winslow GA, et al: A parathyroid hormone–related protein implicated in malignant hypercalcemia: cloning and expression. Science, 1987; 237: 893–896.

  2. Donovan PJ, Sundac L, et al: Calcitriol–mediated hypercalcemia: causes and course in 101 patients. J Clin Endocrinol Metab, 2013; 98: 4023–4029.

  3. Yoshimoto K, Yamasaki R, et al: Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab, 1989; 68: 976–981.

  4. Lumachi F, Brunello A, et al: Medical treatment of malignancy–associated hypercalcemia. Curr Med Chem, 2008; 15: 415–421.

  5. Stewart AF: Clinical practice: Hypercalcemia associated with cancer. N Engl J Med, 2005; 352: 373–379.

  6. Motokura T, Fukumoto S, et al: Parathyroid hormone–related protein in adult T–cell leukemia–lymphoma. Ann Intern Med, 1989; 111: 484–488.

  7. Nagata N, Takeda J, et al: A case of leiomyosarcoma associated with humoral hypercalcemia of malignancy: demonstration of biological and immunological activities of parathyroid hormone–related protein in the tumor extract. Jpn J Cancer Res, 1989; 80: 643–648.

  8. Breslau NA, McGuire JL, et al: Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med, 1984; 100: 1–6.

  9. Kiyokawa T, Yamaguchi K, et al: Hypercalcemia and osteoclast proliferation in adult T–cell leukemia. Cancer, 1987; 59: 1187–1191.

  10. Juppner H, Abou–Samra AB, et al: A G protein–linked receptor for parathyroid hormone and parathyroid hormone–related peptide. Science, 1991; 254: 1024–1026.

  11. Horwitz MJ, Tedesco MB, et al: Direct comparison of sustained infusion of human parathyroid hormone–related protein–(1–36) [hPTHrP–(1–36)] versus hPTH–(1–34) on serum calcium, plasma 1,25–dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab, 2003; 88: 1603–1609.

  12. Abe M, Hiura K, et al: Role for macrophage inflammatory protein (MIP)–1alpha and MIP–1beta in the development of osteolytic lesions in multiple myeloma. Blood, 2002; 100: 2195–2202.

  13. Bataille R, Chappard D, et al: Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest, 1991; 88: 62–66.

  14. Sezer O, Heider U, et al: Human bone marrow myeloma cells express RANKL. J Clin Oncol, 2002; 20: 353–354.

  15. Yin JJ, Selander K, et al: TGF–beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest, 1999; 103: 197–206.

  16. Okada Y, Tsukada J, et al: Macrophage inflammatory protein–1alpha induces hypercalcemia in adult T–cell leukemia. J Bone Miner Res, 2004; 19: 1105–1111.

  17. Wano Y, Hattori T, et al: Interleukin 1 gene expression in adult T cell leukemia. J Clin Invest, 1987; 80: 911–916.

  18. Stewart AF, Horst R, et al: Biochemical evaluation of patients with cancer–associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med, 1980; 303: 1377–1383.

  19. Yeh MW, Ituarte PH, et al: Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab, 2013; 98: 1122–1129.

  20. Zhang SJ, Hu Y, et al: Analysis on survival and prognostic factors for cancer patients with malignancy–associated hypercalcemia. Asian Pac J Cancer Prev, 2014; 14: 6715–6719.

  21. Takeuchi Y, Fukumoto S, et al: Parathyroid hormone–related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. J Bone Miner Res, 2002; 17: 753–757.